VR Logo

Nkarta Inc. (NKTX) download report


Healthcare | Biotechnology & Pharma Research

Nkarta Inc. (NKTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.

IPO Date: 10-Jul-2020

CEO, Pres & Director: Mr. Paul J. Hastings

Chief Financial & Bus. Officer: Dr. Nadir Mahmood Ph.D.

Listing: NASDAQ: NKTX

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.nkartatx.com

Key Facts

Market cap: $637.97 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-92.69 Mln

Cash: $216.96 Mln

Total Debt: $69.25 Mln

Insider's Holding: 7.30%

Liquidity: Low

52 Week range: $7.55 - 40.64

Shares outstanding: 48,404,300

Stock Performance

Time Period Nkarta (NKTX) S&P BSE Sensex S&P Small-Cap 600
YTD-14.14-9.18-18.78
1 month-2.73-4.78-8.00
3 months15.82-9.66-13.65
1 Year-58.410.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Nkarta (NKTX) S&P Small-Cap 600 S&P BSE Sensex
2021-75.0325.2721.99